• Explore /
  • Poster
  • / Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).

Abstract Video & Slides Poster

Authors

null

Akram Mesleh Shayeb

University of California San Diego, Moores Cancer Center, La Jolla, CA

Akram Mesleh Shayeb , Danielle Urman , Nazli Dizman , Luis A Meza , Akhilesh Sivakumar , Chun Loo Gan , Hannah Elizabeth Dzimitrowicz , Tian Zhang , Pedro C. Barata , Mehmet Asim Bilen , Xin Gao , Daniel Yick Chin Heng , Sumanta K. Pal , Marina D. Kaymakcalan , Bradley Alexander McGregor , Toni K. Choueiri , Rana R. McKay

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 291)

DOI

10.1200/JCO.2021.39.6_suppl.291

Abstract #

291

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Lauren Reed-Guy

First Author: Deborah Schrag

First Author: Ulyana Dashkevych

First Author: Irbaz Bin Riaz